Unity Biotechnology Company
Unity Biotechnology finds solutions against age-related diseases, such as vision loss and cognitive decline, cause considerable economic, personal, and societal burdens for individuals, their families, and broader communities. By targeting age-related diseases, we believe that UNITY can treat these diseases, as well as contain healthcare costs and lessen the emotional and societal burden that comes with an aging population.
Investors
Connections from
Funding Status:
Series C
Headquarters:
Brisbane, California, United States
Founded Date:
2009
Employee Number:
51-100
Last Funding Type:
Series C
Total Funding:
210.6M
Estimated Revenue:
$10M to $50M
Industry:
Drug Development, Gene therapy
Investors Number:
23
Technology:
Geroscience
Investor Type:
IPO
Last Funding Date:
Mar 19, 2018
Number Of Exists:
51-100